WALTHAM, Mass.--(BUSINESS WIRE)--March 14, 2006--Interleukin Genetics, Inc. (AMEX: ILI) today reported a net loss of $1.8 million or $0.07 per basic and diluted common share for the quarter ended December 31, 2005. For the year, the company reported a net loss of $6.6 million or $0.28 per basic and diluted common share.
